logo BDSP

Base documentaire

  1. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders.

    Article - En anglais

    The introduction of a new antidepressant, venlafaxine, a serotonin norepinephrine reuptake inhibitor (SNRI), has provided researchers with the opportunity to take a closer look at the issues involved in selecting a product for a formulary.

    To aid decision makers in considering the adoption of this new therapy, a pharmacoeconomic simulation model was developed to evaluate the cost-effectiveness of SNRIs versus traditional oral therapies in the management of patients with major depressive disorders (MDDs) from a cost-based payer perspective.

    Four treatment regimens for MDD were compared : tricyclic antidepressants, selective serotonin reuptake inhibitors, heterocyclic antidepressants, and SNRIs.

    The principles of decision analysis were used to calculate outcome probabilities based on data from a meta-analysis.

    The expected cost of each regimen was calculated using cost data from a survey of three health maintenance organizations located in Missouri, Massachusetts, and California.

    The model suggests that SNRI therapy demonstrates the highest level of cost-effectiveness in an inpatient setting when using both brand and generic acquisition costs of the drugs.

    When comparing treatment regimens for outpatients, the generic heterocyclic antidepressants demonstrate the highest level of cost-effectiveness ; when using brand acquisition costs, the SNRIs demonstrate the highest level of cost-effectiveness.

    Mots-clés Pascal : Antidépresseur, Voie orale, Analyse coût efficacité, Prédiction, Modèle, Etat dépressif, Homme, Etude comparative, Chimiothérapie, Traitement, Inhibiteur recapture, Noradrénaline, Sérotonine, Fluoxétine, Paroxétine, Venlafaxine, Trouble humeur, Métaanalyse, Méthode étude

    Mots-clés Pascal anglais : Antidepressant agent, Oral administration, Cost efficiency analysis, Prediction, Models, Depression, Human, Comparative study, Chemotherapy, Treatment, Reuptake inhibitor, Norepinephrine, Serotonin, Mood disorder, Metaanalysis, Investigation method

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 95-0208598

    Code Inist : 002B02B02. Création : 09/06/1995.